ATE170401T1 - Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände - Google Patents

Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände

Info

Publication number: ATE170401T1
Authority: AT; Austria
Prior art keywords: methods; compositions; hypoglycemia; diabetes mellitus; medical conditions
Prior art date: 1991-03-15

Application number

AT92909629T

Other languages

English (en)

Inventor

Kevin Beaumont

Andrew A Young

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-15

Filing date

1992-03-13

Publication date

1998-09-15

1991-03-15 Priority claimed from US07/670,231 external-priority patent/US5264372A/en

1992-03-13 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

1998-09-15 Application granted granted Critical

1998-09-15 Publication of ATE170401T1 publication Critical patent/ATE170401T1/de

Links

238000000034 method Methods 0.000 title abstract 3
206010012601 diabetes mellitus Diseases 0.000 title abstract 2
230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
208000013016 Hypoglycemia Diseases 0.000 title 1
102000055006 Calcitonin Human genes 0.000 abstract 2
108060001064 Calcitonin Proteins 0.000 abstract 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
229960004015 calcitonin Drugs 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT92909629T 1991-03-15 1992-03-13 Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände ATE170401T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/670,231 US5264372A (en)	1991-03-15	1991-03-15	Receptor-based screening methods for amylin agonists and antagonists
US70499591A	1991-05-24	1991-05-24
US07/774,411 US5321008A (en)	1991-01-10	1991-10-10	Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Publications (1)

Publication Number	Publication Date
ATE170401T1 true ATE170401T1 (de)	1998-09-15

Family

ID=27418205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92909629T ATE170401T1 (de)	1991-03-15	1992-03-13	Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände

Country Status (11)

Country	Link
US (2)	US5321008A (de)
EP (1)	EP0533898B1 (de)
JP (1)	JPH05507943A (de)
AT (1)	ATE170401T1 (de)
AU (1)	AU648895B2 (de)
CA (1)	CA2082928C (de)
DE (1)	DE69226835T2 (de)
DK (1)	DK0533898T3 (de)
ES (1)	ES2122995T3 (de)
MX (1)	MX9201110A (de)
WO (1)	WO1992016222A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992011863A1 (en) *	1991-01-10	1992-07-23	Amylin Pharmaceuticals, Inc.	Amylin activity assays
US5234906A (en) *	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
HU222249B1 (hu) *	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) *	1991-05-24	1998-09-29	Amylin Pharmaceuticals Inc.	Method and composition for treatment of insulin requiring mammals
US5739106A (en) *	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
US6143718A (en)	1995-06-07	2000-11-07	Amylin Pharmaceuticals, Inc.	Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US7101853B2 (en) *	1997-05-06	2006-09-05	Amylin Pharmaceuticals, Inc.	Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) *	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
US5929055A (en) *	1997-06-23	1999-07-27	The Research Foundation Of State University Of New York	Therapeutic method for management of diabetes mellitus
JP4353544B2 (ja) *	1998-01-09	2009-10-28	アミリン・ファーマシューティカルズ，インコーポレイテッド	アミリン作動薬ペプチド用製剤
US6936584B1 (en)	1998-02-13	2005-08-30	Amylin Pharmaceuticals, Inc.	Mixed amylin activity compounds
ES2356595T3 (es)	1998-02-13	2011-04-11	Amylin Pharmaceuticals, Inc.	Nuevos compuestos de actividad mixta de la amilina.
BR0114909A (pt) *	2000-10-26	2004-02-03	Alza Corp	Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
US7655618B2 (en) *	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (en) *	2002-12-27	2004-07-22	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004084859A2 (en) *	2003-03-21	2004-10-07	Nastech Pharmaceutical Company Inc.	Nasal calcitonin formulations containing chlorobutanol
CN101001638A (zh) *	2004-06-29	2007-07-18	迪奥贝克斯公司	用于预防和控制胰岛素诱发的低血糖的组合物和方法
JP2011525895A (ja) *	2008-06-25	2011-09-29	ノボ・ノルデイスク・エー／エス	アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
EP2762150A1 (de) *	2009-03-12	2014-08-06	Nordic Bioscience A/S	Behandlung von Diabetes und Stoffwechselsyndrom
JP7133229B2 (ja)	2017-02-03	2022-09-08	ヴァンダービルトユニバーシティー	糖尿病を治療するためのシステム、組成物および方法
IL282079B2 (en)	2018-10-11	2025-09-01	Intarcia Therapeutics Inc	Human amylin analog polypeptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3171774D1 (en) *	1980-03-31	1985-09-19	Teijin Ltd	Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
EP0348490B1 (de) *	1988-01-11	1995-09-27	Amylin Pharmaceuticals, Inc.	Behandlung von diabetes mellitus typ 2
CA2020786A1 (en) *	1989-07-10	1991-01-11	Amylin Pharmaceuticals, Inc.	Treatment of obesity and essential hypertension and related disorders

1991
- 1991-10-10 US US07/774,411 patent/US5321008A/en not_active Ceased
1992
- 1992-03-13 DK DK92909629T patent/DK0533898T3/da active
- 1992-03-13 JP JP92509074A patent/JPH05507943A/ja active Pending
- 1992-03-13 DE DE69226835T patent/DE69226835T2/de not_active Expired - Fee Related
- 1992-03-13 WO PCT/US1992/002191 patent/WO1992016222A1/en not_active Ceased
- 1992-03-13 AT AT92909629T patent/ATE170401T1/de not_active IP Right Cessation
- 1992-03-13 ES ES92909629T patent/ES2122995T3/es not_active Expired - Lifetime
- 1992-03-13 AU AU16873/92A patent/AU648895B2/en not_active Ceased
- 1992-03-13 MX MX9201110A patent/MX9201110A/es unknown
- 1992-03-13 EP EP92909629A patent/EP0533898B1/de not_active Expired - Lifetime
- 1992-03-13 CA CA002082928A patent/CA2082928C/en not_active Expired - Fee Related
1994
- 1994-06-10 US US08/259,755 patent/US5508260A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5508260A (en)	1996-04-16
AU648895B2 (en)	1994-05-05
CA2082928A1 (en)	1992-09-16
US5321008A (en)	1994-06-14
EP0533898A1 (de)	1993-03-31
EP0533898A4 (en)	1993-10-13
JPH05507943A (ja)	1993-11-11
DE69226835T2 (de)	1999-01-14
DE69226835D1 (de)	1998-10-08
AU1687392A (en)	1992-10-21
ES2122995T3 (es)	1999-01-01
DK0533898T3 (da)	1999-05-31
MX9201110A (es)	1993-07-01
WO1992016222A1 (en)	1992-10-01
CA2082928C (en)	2000-09-05
EP0533898B1 (de)	1998-09-02

Legal Events

Date	Code	Title	Description
1999-02-15	UEP	Publication of translation of european patent specification
2009-12-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE170401T1 (de)	1998-09-15	Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ATE194918T1 (de)	2000-08-15	Behandlung von diabetes
NO940180D0 (no)	1994-01-18	Anvendelse av IGF-I
DE69133595D1 (de)	2008-05-21	Verfahren zur langfristigen Reduktion von Körperfettspeichern, Insulinresistenz, Hyperinsulinämie und Hyperglykämie in Vertebraten
EA200000748A1 (ru)	2000-12-25	Способ введения мономерных аналогов инсулина
DE68929217D1 (en)	2000-07-06	Insulinotropes hormon
DE69132688D1 (de)	2001-09-20	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EA200000041A1 (ru)	2000-08-28	Способ лечения диабета тиазолидиндионом и метформином
ATE271406T1 (de)	2004-08-15	Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils
ES2043890T3 (es)	1994-01-01	Nuevo uso medico.
KR890012667A (ko)	1989-09-18	부작용 예방방법
DE69100282D1 (de)	1993-09-23	Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DK0670729T3 (da)	2001-12-10	Anvendelse af insulin-lignende vækstfaktorer og analoger til behandling af retinale nervesygdomme
EP0766966A3 (de)	2001-02-28	Methode zur Behandlung der Insulinresistenz
DE69841279D1 (de)	2009-12-17	Verwendung von humanem Parathyroid-hormon
PT87523A (pt)	1989-05-31	Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
SK42395A3 (en)	1997-01-08	Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
ATE192656T1 (de)	2000-05-15	Verfahren zur behandlung von patienten mit chronischer lebererkrankung
DE69221725D1 (de)	1997-09-25	Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69728654D1 (de)	2004-05-19	Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
ES2181923T3 (es)	2003-03-01	4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
ATE377424T1 (de)	2007-11-15	Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion
DE3787877D1 (de)	1993-11-25	Filter zur verwendung mit spritze und injektionsnadel.
DE60143278D1 (de)	2010-11-25	Verfahren zur Vorbeugung oder Behandlung von Diabetes
EG19746A (en)	1996-01-31	An artificial pancreas for controlling the blood glucose level in patients for insulin dependant diabetes mellitus